What’s the Buzz

The Bee Healthy Blog

TEST QA SH BLOG POST-04082024-New

TEST QA SH BLOG POST-04082024-New
TEST KeyTakeaway Section Title

TEST KeyTakeaway Section Description

 

Get your FREE prescription discount coupon! Chandrakant

Search your medication below and never pay retail price again. (TEST)

Get your FREE prescription discount coupon! Chandrakant Test

Search your medication below and never pay retail price again. (TEST)

U.S Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for bebtelovimab, a new monoclonal antibody treatment for COVID-19 in adults and children 12 years and older. As the number of infected cases increases daily, the authorization for bebtelovimab comes as great news since the FDA ceased the use of two other monoclonal antibody treatments as of January 22, 2022. Data has shown that the other two treatmentsbamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab)are unlikely to be effective against the COVID-19 omicron variant. 

What you need to know about bebtelovimab:

  • It is a monoclonal antibody therapy that is effective against the omicron variant. 
  • Like other monoclonal antibodies, bebtelovimab are lab-made proteins that mimic the immune system’s ability to fight harmful
TEST Summary Section Title

TEST Summary Section Description 

TEST1

TEST2

TEST3

TEST4